Switching Virally Suppressed HIV-1 Infected Elderly Adults (Age ≥ 60 Years) Without Prior Confirmed Virological Failure From Current Anti-retroviral Regimen to Bictegravir, Emtricitabine and Tenofovir Alafenamide (B/F/TAF)

Status: Completed

Phase of Trial: Phase IV

Latest Information Update: 14 May 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Bictegravir/emtricitabine/tenofovir alafenamide (Primary) ; Dolutegravir; Lamivudine; Tenofovir disoproxil fumarate
Indications HIV-1 infections
Focus Therapeutic Use

Most Recent Events

07 May 2024 Status changed from active, no longer recruiting to completed.
02 Jun 2023 According to ClinicalTrials.gov record, Phase of the study changed from III to IV.
02 Jun 2023 Planned End Date changed from 30 Jun 2023 to 15 Mar 2024.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com

Welcome to AdisInsight